We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 30, 2021

Radiation With or Without Concurrent Trastuzumab for HER2+ DCIS Resected by Lumpectomy

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial
J. Clin. Oncol 2021 Mar 19;[EPub Ahead of Print], MA Cobleigh, SJ Anderson, KP Siziopikou, DW Arthur, R Rabinovitch, TB Julian, DS Parda, SA Seaward, DL Carter, JA Lyons, MS Dillmon, GC Magrinat, VS Kavadi, AM Zibelli, L Tiriveedhi, ML Hill, MK Melnik, S Beriwal, EP Mamounas, N Wolmark

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading